围手术期抗生素能否降低溃疡性皮肤癌切除术后手术部位感染风险?一项严格评价主题
该严格评价主题检索PubMed与Embase,纳入13项英文随机对照试验,评估围手术期局部、口服、肌内、静脉或病灶内抗生素对皮肤科手术(含溃疡性皮肤癌切除)手术部位感染(SSI)的影响。仅1项RCT比较静脉头孢唑林与不用抗生素,显示溃疡性肿瘤SSI率显著降低(P=0·04)。作者认为证据异质性大、缺乏高质量证据,并提出设计良好的多中心RCT的设想。
要点
- 13项RCT中仅2项专门研究溃疡性皮肤癌切除术后的SSI。
- 1项RCT显示静脉头孢唑林较不用抗生素显著降低溃疡性肿瘤SSI率(P=0·04)。
- 作者认为现有证据异质性大,缺乏高质量证据支持围手术期抗生素预防SSI。
核心结论
- 纳入RCT异质性大,难以直接比较所测结局。
- 缺乏高质量证据证明围手术期抗生素可预防溃疡性皮肤癌切除术后SSI。
- 在缺乏证据基础的情况下,作者提出设计良好的多中心RCT可评估溃疡性肿瘤切除术后围手术期抗生素的作用,并可能减少不恰当的抗生素处方。
研究设计与样本
- 研究选择、数据提取与分析由四位作者独立完成。
- 仅纳入英文发表的随机对照试验(RCT)。
- 纳入的患者在皮肤科手术(包括Mohs显微描记手术)中接受围手术期局部、病灶内或口服抗生素。
- 检索PubMed与Embase共识别13项RCT。
- 结局为皮肤病变切除后发生SSI的参与者比例。
主要发现
- 13项RCT分别评估局部(n=5)、口服(n=3)、肌内(n=2)、静脉(n=1)和病灶内抗生素(n=2)使用后的SSI。
- 2项RCT专门研究溃疡性皮肤癌切除术后的SSI。
- 1项RCT在随机接受局部抗生素与口服头孢氨苄的个体中研究专门针对溃疡性皮肤癌手术治疗的SSI率。
- 1项RCT比较静脉头孢唑林与不用抗生素,显示溃疡性肿瘤SSI率显著降低(P=0·04)。
关键数值与推荐
- 静脉头孢唑林 vs 不用抗生素:溃疡性肿瘤SSI率显著降低(P=0·04)。
- 13项RCT中局部抗生素n=5、口服n=3、肌内n=2、静脉n=1、病灶内n=2。
临床怎么用
- 原文未据此给出推荐。
局限性
- 纳入RCT的异质性使所测结局难以直接比较。
- 缺乏高质量证据证明围手术期抗生素可预防溃疡性皮肤癌切除术后SSI。
- 作者提出需设计良好的多中心RCT进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To review the efficacy of perioperative antibiotics in reducing the risk of surgical-site infections (SSIs) following excision of ulcerated skin cancers. SETTING AND DESIGN: Study selection, data extraction and analysis were carried out independently by four authors. Only randomized controlled trials (RCTs) reported in the English language were included. INCLUDED STUDIES: RCTs in the English language in which patients received perioperative topical, intralesional or oral antibiotics for dermatological surgery, including Mohs micrographic surgery in general practice, dermatology or plastic surgery departments, were included. OUTCOME: The proportion of participants developing SSI following excision of skin lesions. RESULTS: Thirteen RCTs were identified from our literature search of PubMed and Embase, which evaluated SSI following use of topical (n = 5), oral (n = 3), intramuscular (n = 2), intravenous (n = 1) and intralesional antibiotics (n = 2) in dermatological surgery. Two RCTs specifically investigated SSIs in ulcerated skin cancer excisions; one RCT investigated the SSI rate following surgical treatment specifically for ulcerated skin cancers in individuals randomized to topical antibiotics vs. oral cephalexin; and one RCT compared intravenous cefazolin with no antibiotic, demonstrating significant reduction in SSI rates for ulcerated tumours (P = 0·04). CONCLUSIONS: The heterogeneity of the RCTs included in this study makes it difficult to make a direct comparison of the outcomes measured. High-quality evidence demonstrating a beneficial effect of the use of perioperative antibiotics to prevent SSI following excision of ulcerated skin cancers is lacking. In the absence of an evidence base, we propose that a well-designed multicentre RCT could evaluate the effect of perioperative antibiotics following excision of ulcerated tumours, and potentially reduce inappropriate antibiotic prescription.
引用
- Chan SA, Wernham AGH, Stembridge N, et al. Do perioperative antibiotics reduce the risk of surgical-site infections following excision of ulcerated skin cancers? A Critically Appraised Topic. Br J Dermatol. 2018. PMID: 29193009. doi:10.1111/bjd.16157
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。